UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 9, 2024

 

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

British Columbia, Canada

 

001-37619

 

N/A

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

100 Spy Court, Markham, Ontario, Canada

 

L3R 5H6

(Address of Principal Executive Offices)

 

(Zip Code)

 

(289) 800-9600

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of exchange on which registered

Common Shares

 

EDSA

 

The NasdaqStock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On February 9, 2024, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2023 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release issued by Edesa Biotech, Inc. dated February 9, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Edesa Biotech, Inc.

 

 

 

 

 

Date: February 9, 2024

By:

/s/ Stephen Lemieux

 

 

Name: 

Stephen Lemieux

 

 

Title:

Chief Financial Officer

 

 

 

3

 

nullv3.24.0.1
Cover
Feb. 09, 2024
Cover [Abstract]  
Entity Registrant Name Edesa Biotech, Inc.
Entity Central Index Key 0001540159
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Feb. 09, 2024
Entity File Number 001-37619
Entity Incorporation State Country Code A1
Entity Address Address Line 1 100 Spy Court
Entity Address City Or Town Markham
Entity Address State Or Province ON
Entity Address Postal Zip Code L3R 5H6
City Area Code 289
Local Phone Number 800-9600
Security 12b Title Common Shares
Trading Symbol EDSA
Security Exchange Name NASDAQ
Entity Address Country CA
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Grafico Azioni Edesa Biotech (NASDAQ:EDSA)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Edesa Biotech
Grafico Azioni Edesa Biotech (NASDAQ:EDSA)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Edesa Biotech